OBI Pharma, Inc. (TPEX:4174)

OBI Pharma Statistics

Total Valuation

OBI Pharma has a market cap or net worth of TWD 5.93 billion. The enterprise value is 5.78 billion.

Market Cap	5.93B
Enterprise Value	5.78B

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

OBI Pharma has 131.48 million shares outstanding. The number of shares has increased by 12.94% in one year.

Current Share Class	131.48M
Shares Outstanding	131.48M
Shares Change (YoY)	+12.94%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	6.45%
Owned by Institutions (%)	3.97%
Float	90.54M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	120.32
PB Ratio	1.92
P/TBV Ratio	2.78
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.45
EV / Sales	117.30
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.91

Financial Position

The company has a current ratio of 5.11, with a Debt / Equity ratio of 0.17.

Current Ratio	5.11
Quick Ratio	4.96
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	-0.27
Interest Coverage	-187.37

Financial Efficiency

Return on equity (ROE) is -78.50% and return on invested capital (ROIC) is -39.93%.

Return on Equity (ROE)	-78.50%
Return on Assets (ROA)	-38.54%
Return on Invested Capital (ROIC)	-39.93%
Return on Capital Employed (ROCE)	-69.80%
Weighted Average Cost of Capital (WACC)	5.39%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.01
Inventory Turnover	5.22

Taxes

In the past 12 months, OBI Pharma has paid 3.22 million in taxes.

Income Tax	3.22M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -63.11% in the last 52 weeks. The beta is 0.27, so OBI Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	-63.11%
50-Day Moving Average	53.46
200-Day Moving Average	60.50
Relative Strength Index (RSI)	29.69
Average Volume (20 Days)	532,936

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OBI Pharma had revenue of TWD 49.29 million and -2.36 billion in losses. Loss per share was -18.24.

Revenue	49.29M
Gross Profit	-82.78M
Operating Income	-2.41B
Pretax Income	-2.54B
Net Income	-2.36B
EBITDA	-2.24B
EBIT	-2.41B
Loss Per Share	-18.24

Balance Sheet

The company has 1.58 billion in cash and 538.29 million in debt, with a net cash position of 1.04 billion or 7.93 per share.

Cash & Cash Equivalents	1.58B
Total Debt	538.29M
Net Cash	1.04B
Net Cash Per Share	7.93
Equity (Book Value)	3.08B
Book Value Per Share	16.63
Working Capital	1.53B

Cash Flow

In the last 12 months, operating cash flow was -1.94 billion and capital expenditures -43.94 million, giving a free cash flow of -1.99 billion.

Operating Cash Flow	-1.94B
Capital Expenditures	-43.94M
Free Cash Flow	-1.99B
FCF Per Share	-15.11

Margins

Gross Margin	-167.96%
Operating Margin	-4,896.63%
Pretax Margin	-5,162.67%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OBI Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.94%
Shareholder Yield	-12.94%
Earnings Yield	-39.82%
FCF Yield	-33.51%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 27, 2026. It was a reverse split with a ratio of 0.5.

Last Split Date	Jan 27, 2026
Split Type	Reverse
Split Ratio	0.5

Scores

OBI Pharma has an Altman Z-Score of 4.61 and a Piotroski F-Score of 2.

Altman Z-Score	4.61
Piotroski F-Score	2